Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07099638 · ClinicalTrials.gov registry record · Phase 2
Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation
A Phase 2 study, sponsored by University of Oklahoma.
- Not yet
- Registry status
- Phase 2
- Development phase
- 496
- Enrollment target
NCT07099638: Clinical Trial Phase 2 study, sponsored by University of Oklahoma.
NCT07099638 is a Phase 2 study that has not yet begun recruiting, run by University of Oklahoma. The registered enrollment target is 496 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (273% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07099638, a Phase 2 study, has not yet begun recruiting, sponsored by University of Oklahoma.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 496 participants
- Enrollment target
Study Summary
Although the prevalence of smoking has declined among U.S. adults, smoking remains the leading preventable cause of cancer incidence and mortality. Quitting smoking increases life expectancy, and quitting at an earlier age is associated with more years of life gained. Effective pharmacotherapies to aid cessation are available, and the combination of behavioral support with pharmacotherapy optimizes cessation outcomes. Varenicline is an effective, first-line smoking cessation treatment, and recent research has investigated combination pharmacotherapy to improve the modest quit rates observed with monotherapy. The findings of two meta-analyses have indicated that varenicline combined with the nicotine patch was more effective than varenicline alone for smoking cessation However, no published studies to date have evaluated the combined impact of varenicline and oral nicotine replacement therapy (NRT) on smoking cessation in a randomized trial. Oral NRT, such as nicotine lozenges, can provide acute relief from cravings/withdrawal, and offers individuals the flexibility to deliver nicotine quickly, in contrast with the continuous, passive, and slow-acting delivery of the nicotine patch. Nevertheless, in clinical trials of other combination pharmacotherapies, participants' adherence to of oral NRT has been suboptimal, making it difficult to determine whether there is an added benefit. Given the near-ubiquity of smartphone ownership (85% of U.S. adults), it is plausible that smartphone-based medication adherence interventions could have a positive influence on pharmacotherapy adherence and smoking cessation. This investigative team has demonstrated the feasibility and potential efficacy of using combination varenicline plus oral NRT treatment to promote smoking cessation in a pilot factorial randomized trial. Likewise, pilot findings showed that medication adherence and smoking cessation rates were higher among those who received smartphone-based medication reminders than
Primary Outcome
Self-reported smoking abstinence over the past 7 days with breath CO≤6 ppm
Interventions
- BEHAVIORAL Telephone Counseling
- DRUG Varenicline (VAR)
- DRUG Nicotine lozenge (NRT)
- BEHAVIORAL Smartphone intervention with adherence components (ADHERE)
- BEHAVIORAL Smartphone intervention without adherence components (NO ADHERE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2026-05 |
| Est. Completion | 2029-06-01 |
| Phase | Phase 2 |
What is known before NCT07099638 opens enrollment
NCT07099638 is an interventional study that assigns participants to a tested intervention. The registered 496 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (273% higher).
The record links to 0 conditions, and to 5 interventions - of which Telephone Counseling is the first listed.
NCT07099638 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07099638 about?
NCT07099638 is a clinical study titled "Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation". Although the prevalence of smoking has declined among U.S. adults, smoking remains the leading preventable cause of cancer incidence and mortality. Quitting smoking increases life expectancy, and quitting at an earlier age is associated with more years of life gained. Effective pharmacotherapies to ...
What is the current status of trial NCT07099638?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 496 participants. The study started on 2026-05. Estimated completion is 2029-06-01.
What interventions are being tested in trial NCT07099638?
The interventions under investigation include: Telephone Counseling (BEHAVIORAL), Varenicline (VAR) (DRUG), Nicotine lozenge (NRT) (DRUG), Smartphone intervention with adherence components (ADHERE) (BEHAVIORAL), Smartphone intervention without adherence components (NO ADHERE) (BEHAVIORAL).
Who is sponsoring clinical trial NCT07099638?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07099638's enrollment target sits among peer trials
496 75th of 2000 higher than 1,925 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- NCT06778447 · 496 participants · NA
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia